These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 9316852)
41. Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys. Xin T; Ai Y; Gerhardt G; Gash D; Zhang Z Biochem Biophys Res Commun; 2008 Jun; 370(3):434-9. PubMed ID: 18381061 [TBL] [Abstract][Full Text] [Related]
42. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. Ohshima-Hosoyama S; Simmons HA; Goecks N; Joers V; Swanson CR; Bondarenko V; Velotta R; Brunner K; Wood LD; Hruban RH; Emborg ME PLoS One; 2012; 7(6):e39036. PubMed ID: 22745701 [TBL] [Abstract][Full Text] [Related]
43. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Lapchak PA; Miller PJ; Jiao S; Araujo DM; Hilt D; Collins F Neurodegeneration; 1996 Sep; 5(3):197-205. PubMed ID: 8910897 [No Abstract] [Full Text] [Related]
44. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Hovland DN; Boyd RB; Butt MT; Engelhardt JA; Moxness MS; Ma MH; Emery MG; Ernst NB; Reed RP; Zeller JR; Gash DM; Masterman DM; Potter BM; Cosenza ME; Lightfoot RM Toxicol Pathol; 2007 Aug; 35(5):676-92. PubMed ID: 17763282 [TBL] [Abstract][Full Text] [Related]
45. Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity. Luz M; Allen PC; Bringas J; Boiko C; Stockinger DE; Nikula KJ; Lewis O; Woolley M; Fibiger HC; Bankiewicz K; Mohr E Arch Toxicol; 2018 Jul; 92(7):2353-2367. PubMed ID: 29785638 [TBL] [Abstract][Full Text] [Related]
46. GDNF-induced cerebellar toxicity: A brief review. Luz M; Mohr E; Fibiger HC Neurotoxicology; 2016 Jan; 52():46-56. PubMed ID: 26535469 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Lapchak PA Rev Neurosci; 1996; 7(3):165-76. PubMed ID: 8916290 [TBL] [Abstract][Full Text] [Related]
48. New treatment improves symptoms of Parkinson's disease. Mayor S BMJ; 2002 Apr; 324(7344):997. PubMed ID: 11976237 [No Abstract] [Full Text] [Related]
50. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712 [TBL] [Abstract][Full Text] [Related]
51. Glial cell line-derived neurotrophic factor protects against ischemia/hypoxia-induced brain injury in neonatal rat. Ikeda T; Xia XY; Xia YX; Ikenoue T; Han B; Choi BH Acta Neuropathol; 2000 Aug; 100(2):161-7. PubMed ID: 10963363 [TBL] [Abstract][Full Text] [Related]